By staying focused on the END goal of freeing millions of patients from the daily burdens of treatment, ENDSULIN is reshaping the way we approach diabetes care. “25 years ago, I thought, ‘Here I am working my butt off for a decade, and I’ve only helped 500 people.’ But millions were suffering.” -Dr. Hans Sollinger, founder & world-leading pancreatic transplant surgeon Every diabetes treatment option comes with cumbersome and severe drawbacks. Founder Hans Sollinger (MD, PhD, Dr hc) and his team have conducted decades of innovative research at the UW Hospitals and Clinics in Madison, searching for a way to make life easier for diabetic patients. Using the most cutting-edge methods in biotechnology, they have finally unlocked a simple and elegant answer: ENDSULIN’s patented gene construct works by re-engineering a small portion of the liver, allowing it to produce and regulate insulin on its own.